The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms
Launched by ENDOLOGIX · Jan 27, 2014
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter, multi-country prospective, single-arm, non-randomized clinical trial. The comparative control arm is a combination of patient data drawn from the abdominal aortic aneurysms (AAA) open surgical control arms of four commercially approved AAA devices as part of the Society of Vascular Surgeons. Patients enrolled in this study will be pre-screened and have a diagnosis of an infrarenal AAA with or without the need for treatment of iliac artery aneurysm, are candidates for endovascular repair, and meet the eligibility criteria. Patients enrolled in the study will participat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years of age
- • Informed consent form understood and signed and patient agrees to all follow-up visits
- • Is able and willing to comply with clinical follow-up requirements for one year
- • Is able and willing to undergo Contrast-Enhanced Spiral CT scans
- • Is a candidate for endovascular repair of an infrarenal aortic aneurysm with or without an iliac aneurysm with at least one of the following;
- • 1. aneurysm ≥ 4.5 cm in diameter, or
- • 2. aneurysm is twice the diameter of the normal infrarenal aorta, or
- • 3. aneurysm is growing at a rate of ≥ 10 % per year
- • Non-aneurysmal aortic neck length ≥ 5mm below the most inferior renal artery
- • Proximal aortic neck diameter between 16 and 36mm
- • Aortic neck angulation to the sac ≤ 60
- • Common iliac artery diameter 8 to 35mm bilaterally
- • Aneurysm blood lumen diameter ≤ 60mm
- • Iliac and femoral arteries suitable for endovascular access with the Nellix System
- Exclusion Criteria:
- • Life expectancy ≤ 1 year
- • Dissecting, ruptured, or leaking aneurysm (blood outside the aorta), has sustained recent trauma, is symptomatic, or is non-degenerative
- • Aneurysm is thoraco-abdominal, suprarenal and/or mycotic
- • Thoracic aneurysm ≥ 4.5cm in diameter
- • AAA requires treatment that would result in bilateral occlusion of the internal iliac arteries
- • Presence of mural thrombus \> 50% circumferentially in aortic neck
- • Iliac aneurysm blood lumen diameter \> 35mm
- • Active infection, vasculitis, or systemic connective tissue disease (e.g., Rheumatoid arthritis, scleroderma, Marfan's syndrome, Ehlers-Danlos disease) at time of procedure
- • History of prior treatment of abdominal aortic or iliac artery aneurysm disease
- • Femoral or iliac artery occlusive disease such that device delivery is not possible
- • Vascular access for delivery of device requires placement of vascular conduit or is through an established vascular graft
- • Receiving dialysis
- • History of hypercoagulability
- • Allergy to IV contrast
- • Serum creatinine level \>2.0 mg/dL (or equivalent)
- • Patient is pregnant or nursing
- • Patient is currently enrolled in an investigational drug or device trial
About Endologix
Endologix is a leading medical device company specializing in innovative solutions for the treatment of vascular diseases, particularly abdominal aortic aneurysms (AAAs). With a commitment to advancing patient care through minimally invasive technologies, Endologix develops and commercializes high-quality endovascular products that enhance clinical outcomes and improve quality of life. The company is dedicated to conducting rigorous clinical trials to ensure the safety and efficacy of its devices, fostering collaboration with healthcare professionals and research institutions to drive innovation in the field of vascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Auckland, , New Zealand
Cali, , Colombia
Riga, , Latvia
Caracas, , Venezuela
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials